Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-07256472
Recifercept · 1 trial · 1 indication
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
Area under the concentration curve from time 0 to end of dosing interval (AUCtau)
Maximum Observed Plasma Concentration directly from data
Time to reach Cmax
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Accumulation ratio was calculated as, Rac obtained from Area Under the Concentration Time Curve (AUC) from time 0-t (Day X) divided by AUC from time 0-t (Day 1).
| Arm | Type | Description |
|---|---|---|
| Low Dose | EXPERIMENTAL | Repeated multiple doses |
| placebo | PLACEBO_COMPARATOR | Repeated multiple doses |
| High Dose | EXPERIMENTAL | Repeated multiple doses |
| Name | Type | Description |
|---|---|---|
| Recifercept | DRUG | recifercept powder for solution for injection |
| Placebo | OTHER | solution for injection |
Inclusion Criteria: * Male participants and female participants of nonchildbearing potential * Participants who are overtly healthy * Capable of giving signed informed consent Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastroint...
Recifercept is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in a Phase 1 clinical trial involving healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
Recifercept is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer sponsored the Phase 1 clinical study of the drug. No partnership or licensing arrangement for Recifercept has been disclosed.
Recifercept is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
Recifercept has been evaluated in one completed Phase 1 trial, NCT04543344, titled a study to evaluate the pharmacokinetic, safety and tolerability of single or multiple subcutaneous doses of Recifercept. The trial enrolled 24 healthy volunteers in Belgium and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial of Recifercept, NCT04543344, was a randomized, double-blind, placebo-controlled study of single or multiple subcutaneous doses. It enrolled 24 healthy volunteers of all sexes, aged 21 years and older, at sites in Belgium. The study has been completed.
Recifercept is not approved. It is an investigational small molecule in Phase 1 clinical development, and its only recorded trial has been completed. Pfizer, Inc. (ticker PFE) is the developer. No regulatory approval for any indication has been announced.